Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance

Eur J Med Res. 2023 Sep 16;28(1):354. doi: 10.1186/s40001-023-01309-x.


Osteosarcoma is the most prevalent and fatal type of bone tumor. Despite advancements in the treatment of other cancers, overall survival rates for patients with osteosarcoma have stagnated over the past four decades Multiple-drug resistance-the capacity of cancer cells to become simultaneously resistant to multiple drugs-remains a significant obstacle to effective chemotherapy. The recent studies have shown that noncoding RNAs can regulate the expression of target genes. It has been proposed that "competing endogenous RNA" activity forms a large-scale regulatory network across the transcriptome, playing important roles in pathological conditions such as cancer. Numerous studies have highlighted that circular RNAs (circRNAs) and long noncoding RNAs (lncRNAs) can bind to microRNA (miRNA) sites as competitive endogenous RNAs, thereby affecting and regulating the expression of mRNAs and target genes. These circRNA/lncRNA-associated competitive endogenous RNAs are hypothesized to play significant roles in cancer initiation and progression. Noncoding RNAs (ncRNAs) play an important role in tumor resistance to chemotherapy. However, the molecular mechanisms of the lncRNA/circRNA-miRNA-mRNA competitive endogenous RNA network in drug resistance of osteosarcoma remain unclear. An in-depth study of the molecular mechanisms of drug resistance in osteosarcoma and the elucidation of effective intervention targets are of great significance for improving the overall recovery of patients with osteosarcoma. This review focuses on the molecular mechanisms underlying chemotherapy resistance in osteosarcoma in circRNA-, lncRNA-, and miRNA-mediated competitive endogenous networks.

Keywords: Chemotherapy resistance; CircRNA; Competitive endogenous RNA; LncRNA; Multidrug resistance; Osteosarcoma; miRNA.

Publication types

  • Review

MeSH terms

  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / genetics
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • MicroRNAs* / genetics
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / genetics
  • RNA, Circular / genetics
  • RNA, Long Noncoding* / genetics
  • RNA, Messenger


  • MicroRNAs
  • RNA, Circular
  • RNA, Long Noncoding
  • RNA, Messenger